Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RJV-217
- Development stage
- Preclinical
- Lead developer
- Rejenevie Therapeutics
- Modality
- Cell Therapies
01
Overview
RJV-217 is a preclinical **cell therapy** candidate from Rejenevie Therapeutics designed for **aged stromal vascular fraction restoration**. The program is described as using **restorative isolated factors** derived from young cells to rejuvenate aged SVF, distinguishing it from related programs that use young mobilized blood directly. Rejenevie lists the therapy for **all Okyanos treating indications**, reflecting intended use across the treatment areas addressed at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas. No explicit molecular target has been disclosed.
- Other names
- aged SVF restoration using restorative isolated factors
Beyond the preview
Go deeper on RJV-217.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RJV-217.